<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208767</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00024913</org_study_id>
    <secondary_id>CVAL489AUS51</secondary_id>
    <nct_id>NCT00208767</nct_id>
  </id_info>
  <brief_title>Effect of Valsartan on Carotid Artery Disease</brief_title>
  <official_title>Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called
      valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan
      will increase the blood levels of markers responsible for repair of the vessel wall, reduce
      oxidation and inflammation, improve the function of the blood vessels, and arrest or slow
      down the progression of atherosclerosis over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis or 'hardening of the arteries' is a process that ultimately leads to the
      development of heart attacks, strokes, poor circulation, and death. Millions of Americans are
      affected by this progressive disease of the arteries. Researchers have tried to understand
      the very complex processes that lead to hardening of the arteries. Part of this research has
      taught the investigators that there are specific molecules that can cause damage or injury to
      the vessel wall by increasing oxidation and inflammation which, in turn, leads to
      atherosclerosis. Other molecules and cells have been found that can actually repair the
      vessel wall.

      Currently, the best treatment the investigators have for preventing or slowing
      atherosclerosis is to control the patients' risk factors such as high blood pressure,
      diabetes, or cholesterol levels using prevention and specific drugs. Angiotensin receptor
      blockers (ARBs) are a class of drugs that have been shown in clinical trials to have many
      beneficial effects in patients with high blood pressure, advanced heart diseases (such as
      after heart attack and heart failure), and diabetes. However, whether these drugs will also
      be useful in people with early signs of hardening of the arteries, measured as a thickening
      of the carotid (neck) arteries is unknown, and is the purpose of this study.

      The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called
      valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan
      will increase the blood levels of markers responsible for repair of the vessel wall, reduce
      oxidation and inflammation, improve the function of the blood vessels, and arrest or slow
      down the progression of atherosclerosis over time.

      In this study, the investigators will recruit subjects who have a hardening or thickening of
      their carotid arteries, one of the main blood vessels in the neck. People will be screened
      with ultrasound or sonar examination for this. Two-thirds of those eligible for participation
      will receive valsartan while the remaining one-third will receive a placebo pill. The
      investigators and subjects will be unaware of which drug is being given until the end of the
      study. The study will last for 2 years. Half of the individuals will also be treated with a
      statin drug (used for cholesterol reduction) and the remaining individuals will not be on a
      statin.

      The investigators will measure carotid artery thickening with magnetic resonance imaging
      (MRI); forearm blood vessel function using ultrasound; and they will perform blood tests to
      measure oxidation and inflammation in the blood stream and circulation stem cells that are
      responsible for healing. These tests will be repeated at 3 months, 1 year and 2 years after
      starting treatment. The investigators will also collect blood for genotyping where the DNA
      will be stored for future analysis to study whether subjects' genotype alters their
      susceptibility to treatments. The investigators' hypothesis is that ARB treated individuals
      will have less oxidation and inflammation, higher levels of stem cells, and a slower
      progression of arterial thickening.

      Finding an early treatment for atherosclerosis would hopefully prevent future strokes, heart
      attacks, and deaths leading to improved longevity and reduced medical expenditure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>The PI will measure carotid artery thickening with magnetic resonance imaging.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Carotid Artery Diseases</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan titrated up to 320 mg orally daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received a placebo instead of Valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan was titrated to a target dose of 320 mg orally daily</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan is a brand name of Valsartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A matched placebo pill will be given orally daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 0.65 mm intima-media thickness of the carotid artery measured by ultrasound

          -  Males aged 21-80 years or women without child bearing potential up to age 80

          -  Can be on concomitant therapy with aspirin, thiazide diuretics, calcium antagonists
             (for treatment of hypertension), or beta-receptor antagonists.

          -  May be on statin if on stable dose for at least 2 months before recruitment

        Exclusion Criteria:

          -  Angiotensin-converting enzyme (ACE) inhibitor or ARB therapy in the previous 3 months.

          -  Initiation or change in dose of statin therapy within 2 months before the study

          -  Inability to return to Emory for follow-up blood drawing and MR imaging

          -  Age &lt; 21 or &gt; 80 years

          -  Premenopausal females with potential for pregnancy

          -  Current neoplasm

          -  Chronic renal failure [creatinine &gt; 2.5 mg/dL]

          -  Diabetes with hemoglobin (Hb) A1c &gt; 8.5

          -  Anticipated change in lipid lowering therapy

          -  Inability to give informed consent

          -  MR exclusion criteria

          -  Blood pressure &gt; 140 mmHg systolic and &gt; 90 mmHg diastolic

          -  Low-density lipoprotein (LDL) cholesterol level &gt;130 mg/dl

          -  Acute coronary syndrome within 2 months

          -  Acute cerebrovascular accident within 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshed Quyyumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>September 12, 2014</results_first_submitted>
  <results_first_submitted_qc>September 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2014</results_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Arshed A. Quyyumi</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Angiotensin receptor blockade</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Emory Healthcare sites or by advertisement between March 2005 and October 2008.</recruitment_details>
      <pre_assignment_details>60 of the enrolled subjects were already on long-term statin therapy and were stratified for statin use before randomization. Subjects on statin therapy were switched to simvastatin 40 mg daily unless they were already on high dose statin therapy and thus were placed on 80 mg daily of simvastatin for the duration of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Valsartan</title>
          <description>Valsartan titrated up to 320 mg orally daily
Valsartan: Valsartan was titrated to a target dose of 320 mg orally daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients received a placebo instead of Valsartan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valsartan</title>
          <description>Valsartan titrated up to 320 mg orally daily
Valsartan: Valsartan was titrated to a target dose of 320 mg orally daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients received a placebo instead of Valsartan</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="9"/>
                    <measurement group_id="B2" value="62" spread="9"/>
                    <measurement group_id="B3" value="60" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years</title>
        <description>The PI will measure carotid artery thickening with magnetic resonance imaging.</description>
        <time_frame>Baseline, 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valsartan</title>
            <description>Valsartan titrated up to 320 mg orally daily
Valsartan: Valsartan was titrated to a target dose of 320 mg orally daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received a placebo instead of Valsartan</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years</title>
          <description>The PI will measure carotid artery thickening with magnetic resonance imaging.</description>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="2.4"/>
                    <measurement group_id="O2" value="3.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valsartan</title>
          <description>Valsartan titrated up to 320 mg orally daily
Valsartan: Valsartan was titrated to a target dose of 320 mg orally daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients received a placebo instead of Valsartan</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Majory injury/accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arshed Quyyumi</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-727-3655</phone>
      <email>aquyyum@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

